Makita Shinichi, Maruyama Dai, Tobinai Kensei
Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Onco Targets Ther. 2020 Jun 23;13:5993-6009. doi: 10.2147/OTT.S193951. eCollection 2020.
Classical Hodgkin lymphoma (cHL) is a B-cell-derived lymphoid malignancy with the most favorable prognosis among various adult malignancies. However, once it becomes refractory disease to chemotherapy or relapses after high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT), it is difficult to manage with conventional cytotoxic chemotherapy. The introduction of brentuximab vedotin (BV) has changed the treatment landscape of cHL in the past decade. Several studies demonstrated high efficacy of BV monotherapy in heavily treated patients with cHL relapsed or refractory after HDC/ASCT. Recent studies also reported high efficacy of concurrent or sequential combination of BV and chemotherapy in patients with transplant-eligible relapsed/refractory cHL at the second-line setting. In addition, a randomized phase III trial ECHELON-1 reported a positive result of BV in combination with AVD (doxorubicin, vinblastine, and dacarbazine) in patients with newly diagnosed advanced-stage cHL. In this review, we summarize available data of BV for cHL and discuss the current and future role of BV in the management of cHL.
经典型霍奇金淋巴瘤（cHL）是一种起源于B细胞的淋巴恶性肿瘤，在各种成人恶性肿瘤中预后最为良好。然而，一旦它对化疗产生耐药或在接受大剂量化疗（HDC）联合自体干细胞移植（ASCT）后复发，使用传统的细胞毒性化疗就很难进行治疗。在过去十年中，维布妥昔单抗（BV）的引入改变了cHL的治疗格局。多项研究表明，BV单药治疗对接受过强化治疗且在HDC/ASCT后复发或难治的cHL患者具有高效。近期研究还报告称，在二线治疗中，BV与化疗同时或序贯联合应用于符合移植条件的复发/难治性cHL患者时疗效显著。此外，一项随机III期试验ECHELON-1报告了BV联合AVD（多柔比星、长春碱和达卡巴嗪）治疗初诊晚期cHL患者的阳性结果。在本综述中，我们总结了BV治疗cHL的现有数据，并讨论了BV在cHL治疗中的当前及未来作用。
